drugset / Trial / NCT04435392

Jaktinib Hydrochloride Cream For Atopic Dermatitis

NCT04435392

Phase 1/2 Completed 107 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This study includes a dose escalation part and a dose extension part.

Timeline

Start
2020-10-14
Primary completion
2022-09-08
Completion
2022-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown 0.5 % Topical
Subject Jaktinib Unknown 1.5 % Topical
Subject Jaktinib Unknown 2.5 % Topical

Indications